199657-29-9
| 中文名稱 | 199657-29-9 |
|---|---|
| 中文同義詞 | 化合物 T6279L;化合物GIVINOSTAT HYDROCHLORIDE;化合物GIVINOSTAT HYDROCHLORIDE,10 MM DMSO 溶液;(6-((二乙基氨基)甲基)萘-2-基)甲基 (4-(羥基氨基甲?;?苯基)氨基甲酸酯鹽酸鹽 |
| 英文名稱 | Givinostat hydrochloride |
| 英文同義詞 | Givinostat (hydrochloride);[6-[(Diethylamino)methyl]-2-naphthalenyl]methyl-N-[4-[(hydroxyamino)carbonyl]phenyl]carbamate hydrochloride;Givinostat (ITF2357) HCl;Gavinostat hydrochloride;GAVINOSTAT HYDROCHLORIDE;ITF-2357 HYDROCHLORIDE;ITF-2357 hydrochloride;Givinostat (ITF2357) hydrochloride;Givinostat HCl. gavinostat |
| CAS號 | 199657-29-9 |
| 分子式 | C24H28ClN3O4 |
| 分子量 | 457.96 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 199657-29-9.mol |
| 結(jié)構(gòu)式 | ![]() |
199657-29-9 性質(zhì)
| 儲存條件 | Store at -20°C |
|---|---|
| 溶解度 | DMSO:45.8(最大濃度 mg/mL);100.01(最大濃度 mM) |
| 形態(tài) | Solid |
| 顏色 | White to off-white |
|
hHDAC3 157 nM (IC 50 ) |
hHDAC1 198 nM (IC 50 ) |
hHDAC11 292 nM (IC 50 ) |
hHDAC6 315 nM (IC 50 ) |
hHDAC2 325 nM (IC 50 ) |
hHDAC10 340 nM (IC 50 ) |
hHDAC7 524 nM (IC 50 ) |
hHDAC5 532 nM (IC 50 ) |
hHDAC9 541 nM (IC 50 ) |
hHDAC8 854 nM (IC 50 ) |
hHDAC4 1059 nM (IC 50 ) |
HD1-B 7.5 nM (IC 50 ) |
HD1-A 16 nM (IC 50 ) |
HD2 10 nM (IC 50 ) |
Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduces IL-1β secretion more than 70%. Givinostat suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 100 and 200 nM, there is no reduction. Givinostat (ITF-2357) inhibits JS-1 cell proliferation in a concentration-dependent manner in the CCK-8 assay. Treatment with Givinostat (ITF-2357) ≥500 nM is associated with significant inhibition of JS-1 cell proliferation. Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat (ITF-2357) ≥250 nM plus LPS and the group without LPS treatment.
Givinostat (ITF2357) at 10 mg/kg is used as a positive control and reduces serum TNFα by 60%. Pretreatment of Givinostat (ITF-2357) starting at 0.1 mg/kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg/kg), and blood is collected after 4 h.
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-14842A | 199657-29-9 Givinostat hydrochloride | 199657-29-9 | 5 mg | 890元 |
| 2026/06/05 | HY-14842A | 199657-29-9 Givinostat hydrochloride | 199657-29-9 | 10 mM * 1 mLin DMSO | 897元 |
